登录 查看公司和协议定价
选择尺寸
关于此项目
经验公式(希尔记法):
C28H25FN6O3
化学文摘社编号:
分子量:
512.53
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77
质量水平
方案
≥98% (HPLC)
表单
powder
颜色
yellow to orange
溶解性
DMSO: 10 mg/mL, clear
储存温度
−20°C
SMILES字符串
O=C(N1CCCCC1)N(C2)CCN3C4=C2C=C(F)C=C4C(C5=C(C6=CN=C7N6C=CC=C7)C(NC5=O)=O)=C3
InChI
1S/C28H25FN6O3/c29-18-12-17-15-34(28(38)32-7-3-1-4-8-32)11-10-33-16-20(19(13-18)25(17)33)23-24(27(37)31-26(23)36)21-14-30-22-6-2-5-9-35(21)22/h2,5-6,9,12-14,16H,1,3-4,7-8,10-11,15H2,(H,31,36,37)
InChI key
HRJWTAWVFDCTGO-UHFFFAOYSA-N
基因信息
human ... GSK3A(2931), GSK3B(2932)
相关类别
生化/生理作用
LY2090314 can decrease the development of human MYCN amplified and non-amplified neuroblastoma (NB) cell lines in vitro. It has the ability to prevent the multiplication, colony formation and cell confluency of neuroblastoma.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3) currently in clinical trials for cancer therapy. LY2090314 has IC50 values of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β, respectively.
LY2090314 is a potent and selective ATP-competitive inhibitor of Glycogen synthase kinase-3 (GSK-3).
警示用语:
Warning
危险声明
危险分类
Acute Tox. 4 Oral
储存分类代码
11 - Combustible Solids
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Antiproliferative and apoptotic effect of LY2090314, a GSK-3 inhibitor, in neuroblastoma in vitro
Kunnimalaiyaan S, et al.
BMC Cancer, 18(1), 560-560 (2018)
Mengfei Yu et al.
Cell, 184(1), 243-256 (2021-01-09)
Craniosynostosis results from premature fusion of the cranial suture(s), which contain mesenchymal stem cells (MSCs) that are crucial for calvarial expansion in coordination with brain growth. Infants with craniosynostosis have skull dysmorphology, increased intracranial pressure, and complications such as neurocognitive
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持